Prestige Consumer Earnings Reports

Prestige Consumer Healthcare Inc. surpassed sales and earnings expectations in Q2 fiscal 2026, driven by Clear Eyes® supply timing and retailer orders. The company maintained its financial profile and repurchased shares, while reaffirming its fiscal 2026 revenue outlook and updating its Adjusted Diluted EPS outlook to the high end of the previous range.

Prestige Consumer Healthcare Inc. reported a revenue of $249.5 million for the first quarter of fiscal 2026, a decrease of 6.6% year-over-year, mainly due to limited supply of Clear Eyes. Despite this, diluted EPS increased by approximately 6% to $0.95, and non-GAAP free cash flow saw a significant increase to $78.2 million. The company also announced the acquisition of Pillar5 Pharma to secure eye care production capacity and revised its full-year fiscal 2026 revenue and EPS outlook.

Prestige Consumer Healthcare Inc. delivered another year of consistent sales and earnings per share growth, with record fourth quarter sales performance driven by International business strength, growth in various categories and brands in North America, and success in eCommerce.

Prestige Consumer Healthcare Inc. reported a 2.7% increase in revenue to $290.3 million and diluted EPS of $1.22, up approximately 15% year-over-year. The company raised its full-year fiscal 2025 earnings outlook, driven by strong free cash flow and debt reduction.

Prestige Consumer Healthcare reported Q2 2025 revenue of $283.8 million, a slight decrease of 0.9% year-over-year, but ahead of expectations. Diluted EPS increased by 2% to $1.09. The company reaffirmed its full-year fiscal 2025 revenue, earnings, and cash flow outlook.

Prestige Consumer Healthcare reported first quarter fiscal 2025 results with revenue of $267.1 million and EPS of $0.98. The company reaffirmed its full-year fiscal 2025 revenue, earnings, and cash flow outlook. Strong cash generation allowed for debt reduction and share repurchases.